Global GLP-1 Receptor Agonist (Ozempic, Rybelsus, Trulicity, Saxenda, Wegovy, Victoza, Mounjaro, Zepbound) Market Analysis Report 2024-2030 Featuring Eli Lilly and C, Sanofi, Novo Nordisk, AstraZeneca Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Global GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Type 2...

GLP-1 Receptor Agonist Market on the Rise with Anticipated Surge to $16.82 Billion by 2028 Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global market for GLP-1 receptor...

ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for...

ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...

ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control...